The complement system is a part of the immune system that enhances (complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, ... Complement ...

Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and ...

In short, this protein activates the full complement cascade. ... RA, the vasculitides and other autoimmune diseases, that the antibodies drive the classical pathway.

C1q is the initiating molecule of the classical complement cascade believed to cause the immune response responsible for GBS. The randomized, double-blind, placebo-controlled study ...

Yednock T, Fong DS, Lad EM. C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration.

Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and ...

Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein. Journal: Proceedings of the National Academy of Sciences of the United States ...

ANX005 is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and nerve ...

Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade. With a single infusion, ...

Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade. In the Phase 3 pivotal trial of 241 patients, ...

Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ...

ANX005 is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade, with a single infusion to halt ongoing neuroinflammation and nerve ...